GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Ligand Pharmaceuticals Incorporated (LGND) [hlAlert]

Rating:
Buy LGND
up 913.44 %

Ligand Pharmaceuticals Incorporated (LGND) rated Buy with price target $24 by C.K. Cooper

Posted on: Tuesday,  Jul 26, 2011  3:25 PM ET by C.K. Cooper

C.K. Cooper rated Buy Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on 07/26/2011. Previously C.K. Cooper rated Buy Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on
06/17/2010., when the stock price was $9.30. Since then, Ligand Pharmaceuticals Incorporated has gained 913.44% as of 09/30/2015's recent price of $94.25.
If you would have followed the previous C.K. Cooper's recommendation on LGND, you would have gained 913.44% of your investment in 1931 days.

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

C. K. Cooper & Company has for over a decade provided insightful research ideas and commentary. As the firm identifies focus industries it brings together an analytical team to provide unique vision and insight to select investment ideas. In addition, leveraging on the expertise of the firm, the Research Team can evaluate opportunities against a wide database of industry and competitive trends.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/26/2011 3:25 PM Buy
None
13.34 24.00
as of 12/30/2011
1 Week up  0.67 %
1 Month up  1.19 %
3 Months down  -13.23 %
1 YTD up  33.07 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/12/2011 2:25 PM Buy
None
9.68 21.00
6/17/2010 8:25 AM Buy
None
9.30 19.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy